Date: 2016-08-04
Type of information: Licensing agreement
Compound: fully-human binding domain targeting B-cell maturation antigen (BCMA) and binding domains against two additional undisclosed multiple myeloma targets
Company: Juno Therapeutics (USA - WA) Memorial Sloan Kettering Cancer Center (USA - NY) Eureka Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: gene therapy/cell immunotherapy/cell therapy.
Disease: multiple myeloma
Details:
- • On August 4, 2016, Juno Therapeutics announced that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma. The binding domains were developed under a collaboration agreement between Eureka Therapeutics and MSK. The parties expect the BCMA CAR to enter human testing as early as 1H2017.
Financial terms:
- Memorial Sloan Kettering Cancer Center and Eureka Therapeutics are eligible to receive an undisclosed upfront payment, additional payments upon the achievement of undisclosed clinical, regulatory, and commercial milestones, and royalties on net sales.
Latest news:
Is general: Yes
